Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Standard of care and progress with PARP inhibitors for ovarian cancer

Susana Banerjee • 21 Oct 2018
ESMO 2018
Gynecological Cancer Ovarian Cancer Olaparib

Susana Banerjee, MBBS, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, about the standard of care and progress with PARP inhibitors for ovarian cancer.

More from Susana Banerjee

2:06
Women for Oncology: initiatives at ESMO 2018
Susana Banerjee • 21 Oct 2018
3:38
SOLO-1: practice changing results for advanced ovarian cancer
Susana Banerjee • 21 Oct 2018

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals